IL1B and pneumonia: The treatment of these aged mice with inflammasome activators [Nigericin, which promotes potassium (K+) efflux increases the synthesis and release of inflammasome activation-dependent cytokines (IL-1β and IL-18)] increase their survival and decreases their susceptibility toward pneumonia and ALI.